Rational Design, Synthesis, in Vitro, and in Silico Studies of Dihydropyrimidinone Derivatives as β -Glucuronidase Inhibitors

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the current study, a series of dihydropyrimidinone derivatives were rationally designed as β-glucuronidase inhibitors. These designed compounds were successfully synthesized and characterized through various spectroscopic techniques such as IR, 1H-NMR, 13C-NMR, and EI-MS. A structure-activity relationship (SAR) of synthesized derivatives to inhibit β-glucuronidase was also established. In vitro biological evaluations revealed that 4i as the most potent compound in this series has an IC50 value of 31.52 ± 2.54 μM compared to the standard D-saccharic acid 1,4-lactone (IC50 = 41.32 ± 1.82 μM). Also, molecular docking and dynamics studies of the most potent compound are performed to evaluate interactions between the active compound and binding site.

Cite

CITATION STYLE

APA

Karimian, S., Moghdani, Y., Khoshneviszadeh, M., Pirhadi, S., Iraji, A., & Khoshneviszadeh, M. (2021). Rational Design, Synthesis, in Vitro, and in Silico Studies of Dihydropyrimidinone Derivatives as β -Glucuronidase Inhibitors. Journal of Chemistry, 2021. https://doi.org/10.1155/2021/6664756

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free